Sermorelin Geriatric (65+) Dosing

Why Geriatric Dosing Differs From Standard Adult Protocols

Growth hormone secretion declines roughly 14% per decade after age 30, a phenomenon termed somatopause [1]. By age 65, pulsatile GH output may be 50 to 70% lower than peak young-adult levels. Sermorelin, a 29-amino-acid analogue of growth hormone-releasing hormone (GHRH 1-29), stimulates the anterior pituitary to release endogenous GH. The drug depends on a functioning pituitary gland, and pituitary reserve itself diminishes with age.

That declining reserve changes the dose-response curve. A 300 mcg dose that produces a strong GH pulse in a 40-year-old may provoke only a blunted response in a 70-year-old, or it could cause fluid retention and arthralgia if the older patient's clearance is slower than expected. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends starting GH replacement at lower doses in older patients and titrating based on IGF-1, not weight [2]. While that guideline addresses recombinant GH rather than secretagogues, the physiologic rationale carries over: older tissues respond differently to GH-axis stimulation.

Renal clearance matters too. Sermorelin is a peptide cleared partly through renal filtration. Age-related GFR decline means the peptide's half-life (which is already short at 10 to 20 minutes) may shift enough to alter peak serum concentrations. A 2017 review in the Journal of Clinical Endocrinology & Metabolism confirmed that GH-axis peptides require renal-adjusted dosing in patients with eGFR below 45 mL/min/1.73 m² [3].

Recommended Starting Dose and Titration Schedule

For adults 65 and older, most compounding pharmacy protocols and clinical references suggest initiating sermorelin at 100 to 200 mcg subcutaneously once daily at bedtime. This is the lower half of the typical adult range (100 to 500 mcg). The bedtime timing aligns injection with the natural nocturnal GH pulse.

Titration should happen slowly. A reasonable schedule:

• Weeks 1 to 4: 100 mcg nightly. Assess tolerability (injection-site reactions, headache, fluid retention).
• Weeks 5 to 8: If tolerated and IGF-1 remains below the age-adjusted midrange, increase to 200 mcg nightly.
• Weeks 9 to 12: Recheck IGF-1 and fasting glucose. If IGF-1 is still suboptimal and no adverse effects are present, the clinician may consider 300 mcg nightly.
• Beyond week 12: Doses above 300 mcg are rarely justified in this age group. If no meaningful IGF-1 response occurs at 300 mcg, reassess pituitary reserve with a GH stimulation test.

The target IGF-1 range for older adults is the age-adjusted reference interval, not the upper quartile targeted in younger patients. Pushing IGF-1 above the age-adjusted 75th percentile in patients over 65 has been associated with increased insulin resistance and theoretical oncologic concern in observational data [4].

Renal Function and Dose Adjustments

Chronic kidney disease (CKD) prevalence exceeds 38% in adults over 65, according to CDC NHANES data [5]. Because sermorelin clearance involves renal mechanisms, prescribers must check estimated GFR before initiation and periodically during therapy.

Practical thresholds:

• eGFR ≥60 mL/min: Standard geriatric starting dose (100 to 200 mcg).
• eGFR 30 to 59 mL/min (CKD stage 3): Start at 100 mcg. Extend titration intervals to every 6 to 8 weeks. Monitor for fluid retention closely.
• eGFR <30 mL/min (CKD stages 4 to 5): Sermorelin is generally not recommended. The GH-IGF-1 axis is profoundly disrupted in advanced CKD, and stimulating GH release in this context may worsen glucose dysregulation without meaningful anabolic benefit.

A 2020 analysis of GH-axis modulation in CKD patients published in Kidney International Reports noted that GH resistance in uremia limits the effectiveness of upstream secretagogues like GHRH analogues [6]. This finding reinforces the recommendation to avoid sermorelin in advanced renal disease rather than simply dose-reduce.

Polypharmacy and Drug Interaction Considerations

Adults over 65 take a median of five prescription medications. Several common drug classes interact with the GH-IGF-1 axis.

Glucocorticoids suppress GH secretion and blunt the pituitary's response to GHRH. Patients on chronic prednisone (≥5 mg/day equivalent) may see minimal benefit from sermorelin. If glucocorticoid tapering is not feasible, sermorelin therapy should be reconsidered. The Endocrine Society guidelines specifically note that glucocorticoid excess must be addressed before diagnosing or treating adult GHD [2].

Insulin and sulfonylureas create a bidirectional interaction. GH raises fasting glucose. Sermorelin-induced GH pulses could destabilize glycemic control in patients with type 2 diabetes. Close glucose monitoring (every 2 weeks initially) is warranted, and insulin doses may need upward adjustment.

Somatostatin analogues (octreotide, lanreotide), used for neuroendocrine tumors or acromegaly, directly oppose sermorelin's mechanism. Co-prescribing is pharmacologically contradictory.

Thyroid hormone replacement affects GH-axis responsiveness. Hypothyroid patients convert less T4 to T3, and GH replacement (or stimulation) can unmask central hypothyroidism. Check TSH and free T4 at baseline and 8 to 12 weeks into therapy [2].

Monitoring Protocol for Patients Over 65

A structured monitoring schedule reduces risk. The following protocol reflects both the Endocrine Society's adult GHD guideline recommendations and clinical experience with compounded peptide therapy:

Baseline labs (before first injection):

• IGF-1
• Comprehensive metabolic panel (includes creatinine, eGFR, fasting glucose)
• HbA1c
• TSH, free T4
• Lipid panel
• PSA (males)

At 8 to 12 weeks:

• IGF-1 (primary efficacy marker)
• Fasting glucose or HbA1c
• Comprehensive metabolic panel
• TSH, free T4

Every 6 months thereafter:

• Repeat the 8 to 12 week panel
• Bone density (DEXA) annually if osteoporosis is a co-indication
• PSA annually in males

The target is an IGF-1 in the middle tertile of the age-adjusted reference range. An IGF-1 persistently in the upper quartile warrants dose reduction regardless of symptoms. Conversely, a flat IGF-1 response after 12 weeks at 200 to 300 mcg suggests diminished pituitary reserve, and continuing sermorelin offers little benefit.

Falls, Fractures, and the Musculoskeletal Angle

One rationale for GH-axis therapy in older adults is musculoskeletal preservation. GH stimulates osteoblast activity, and IGF-1 promotes muscle protein synthesis. A 2007 meta-analysis in the Annals of Internal Medicine examined GH therapy in healthy older adults and found that lean body mass increased by approximately 2.0 kg, but strength gains were inconsistent, and adverse events (edema, arthralgias, carpal tunnel symptoms) were significantly more common [7].

These findings apply to exogenous recombinant GH rather than GHRH analogues like sermorelin. Sermorelin's physiologic feedback mechanism (it stimulates endogenous release rather than bypassing pituitary regulation) theoretically limits supraphysiologic GH spikes. Still, the musculoskeletal benefits in geriatric patients remain unproven in controlled trials.

For fall prevention specifically, no study has demonstrated that sermorelin reduces fall incidence. The CDC reports that one in four Americans aged 65 and older falls each year [8]. Fluid retention and transient dizziness, both potential sermorelin side effects, could transiently increase fall risk. Monitor ambulatory patients for lower-extremity edema during the first month.

Deprescribing: When to Stop Sermorelin

Not every medication started in a patient's 60s remains appropriate at 75 or 80. Deprescribing sermorelin should be discussed when:

• No measurable IGF-1 response after 12 weeks at adequate doses (≥200 mcg). Pituitary exhaustion makes continued use futile.
• New-onset diabetes or worsening glycemic control attributable to GH-mediated insulin resistance.
• Cancer diagnosis. While the relationship between GH/IGF-1 and cancer is complex, most oncologists prefer to discontinue GH-axis stimulation during active malignancy. The 2011 Endocrine Society guideline recommends against GH replacement in patients with active cancer [2].
• Advanced CKD progression. If eGFR drops below 30 mL/min during therapy, discontinue sermorelin.
• Patient preference or injection fatigue. Daily subcutaneous injections become burdensome. If a patient is missing more than two doses per week consistently, the intermittent dosing pattern may produce negligible benefit.
• Functional decline. If the original goal was body composition or functional performance and those endpoints have plateaued or worsened despite 6+ months of therapy, continuing is not justified.

Stopping sermorelin requires no taper. It can be discontinued abruptly. The pituitary will revert to its baseline GH secretion pattern within days.

What the Evidence Actually Shows

The clinical trial base for sermorelin in geriatric populations is thin. Walker et al. (1990) demonstrated sermorelin's efficacy in pediatric GHD, showing improved growth velocity in children, but this study has no direct applicability to adults over 65 [9]. The key pediatric work led to sermorelin's brief FDA approval (as Geref Diagnostic and then Geref), but the commercial product was discontinued in 2008.

A small 1998 study by Vittone et al. in the Journal of Clinical Endocrinology & Metabolism administered GHRH (1-29) to men aged 64 to 76 at bedtime for 16 weeks [10]. GH secretion increased during sleep, and IGF-1 rose modestly. However, the sample was small (N=9 in the treatment group), and no functional outcomes (strength, body composition, cognition) were powered for detection.

Corpas et al. (1993) studied twice-daily GHRH(1-29) (subcutaneous, 10 mcg/kg) in healthy men aged 60 to 80 over 14 days. IGF-1 increased by approximately 35%, and GH pulse amplitude improved [11]. Again, the study was brief and small. No long-term safety data in geriatric populations exist.

Dr. George Merriam, who led several early GHRH trials in older adults at the University of Washington, stated in a 1997 review: "GHRH administration can partially restore the GH secretory pattern of aging, but whether this translates to clinically meaningful functional benefits remains unproven" [12].

The American Association of Clinical Endocrinologists (AACE) does not include sermorelin in its 2019 growth hormone guidelines, which focus on FDA-approved recombinant GH products [13]. This omission reflects sermorelin's regulatory status (compounded, not FDA-approved for adult use) rather than a specific safety concern.

Injection Technique for Older Adults

Subcutaneous injection technique deserves attention in patients over 65. Age-related skin thinning, reduced subcutaneous fat, and arthritic hand changes affect self-injection capability.

Practical guidance:

• Use a 29- or 30-gauge, 0.5-inch needle. Shorter needles reduce the risk of inadvertent intramuscular injection in thin patients.
• Preferred sites: abdomen (avoiding a 2-inch radius around the navel) and anterior thigh. Rotate sites with each injection.
• If hand dexterity limits syringe use, assess whether a caregiver can assist. Pen-style devices, common for insulin, are not currently available for compounded sermorelin.
• Store reconstituted sermorelin refrigerated at 2 to 8°C. Peptide stability declines with temperature excursion. Patients should not store vials in the refrigerator door, where temperature fluctuates.

Off-Label Rationale and Informed Consent

Sermorelin prescribed through 503A compounding pharmacies for adult growth hormone deficiency (or age-related GH decline) is off-label. The FDA has not approved sermorelin for this indication. Informed consent should document:

1. The absence of large controlled trials in adults over 65.
2. Compounded drug quality depends on the pharmacy's compliance with USP 797/800 standards.
3. Expected benefits are modest and not guaranteed: potential improvements in body composition, sleep quality, and skin thickness based on small studies.
4. Risks include fluid retention, arthralgia, injection-site reactions, glucose dysregulation, and unknown long-term effects.
5. Alternative options include FDA-approved recombinant GH (somatropin) for diagnosed adult GHD, which has a more strong evidence base.

A shared decision-making conversation is the appropriate standard. The patient should understand that sermorelin is neither a longevity drug with guaranteed outcomes nor an unreasonable therapy. It is an option with limited evidence, physiologic plausibility, and a favorable short-term safety profile at low doses.

The 2019 Endocrine Society position statement on GH misuse notes that prescribing GH-axis therapies for "anti-aging" without documented GHD falls outside evidence-based practice [14]. Clinicians should document objective findings supporting GH deficiency (low IGF-1, failed stimulation test) before initiating therapy.

Sermorelin 100 mcg subcutaneously at bedtime, titrated by IGF-1 every 4 to 6 weeks, with renal monitoring and a polypharmacy review, represents the most defensible starting approach for adults 65 and older.